Modality
mRNA
MOA
HER2
Target
C5
Pathway
Sphingolipid
AsthmaCeliacPNH
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
Jan 2019
→ Mar 2029
Phase 1Current
NCT03372204
2,579 pts·Celiac
2019-01→TBD·Not yet recruiting
NCT05967521
481 pts·Celiac
2020-02→2029-03·Completed
3,060 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-273.0y awayInterim· Celiac
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1
Not yet…
P1
Complet…
Catalysts
Interim
2029-03-27 · 3.0y away
Celiac
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03372204 | Phase 1 | Celiac | Not yet recr... | 2579 | LiverFat |
| NCT05967521 | Phase 1 | Celiac | Completed | 481 | Safety |
Competitors (10)